- Home
- MEGI vs REPL Comparison
MEGI vs REPL Comparison
Compare MEGI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGI
- REPL
- Stock Information
- Founded
- MEGI 2021
- REPL 2015
- Country
- MEGI United States
- REPL United States
- Employees
- MEGI N/A
- REPL N/A
- Industry
- MEGI Investment Managers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MEGI Finance
- REPL Health Care
- Exchange
- MEGI Nasdaq
- REPL Nasdaq
- Market Cap
- MEGI 764.1M
- REPL 816.4M
- IPO Year
- MEGI N/A
- REPL 2018
- Fundamental
- Price
- MEGI $13.36
- REPL $10.80
- Analyst Decision
- MEGI
- REPL Strong Buy
- Analyst Count
- MEGI 0
- REPL 4
- Target Price
- MEGI N/A
- REPL $17.00
- AVG Volume (30 Days)
- MEGI 178.0K
- REPL 432.6K
- Earning Date
- MEGI 01-01-0001
- REPL 11-12-2024
- Dividend Yield
- MEGI 11.40%
- REPL N/A
- EPS Growth
- MEGI N/A
- REPL N/A
- EPS
- MEGI N/A
- REPL N/A
- Revenue
- MEGI N/A
- REPL N/A
- Revenue This Year
- MEGI N/A
- REPL N/A
- Revenue Next Year
- MEGI N/A
- REPL $469.74
- P/E Ratio
- MEGI N/A
- REPL N/A
- Revenue Growth
- MEGI N/A
- REPL N/A
- 52 Week Low
- MEGI $10.63
- REPL $4.92
- 52 Week High
- MEGI $14.89
- REPL $12.97
- Technical
- Relative Strength Index (RSI)
- MEGI 34.43
- REPL 38.50
- Support Level
- MEGI $13.60
- REPL $11.45
- Resistance Level
- MEGI $13.92
- REPL $12.73
- Average True Range (ATR)
- MEGI 0.25
- REPL 0.69
- MACD
- MEGI -0.08
- REPL -0.16
- Stochastic Oscillator
- MEGI 21.92
- REPL 8.82
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
MainStay CBRE Global Infrastructure Megatrends Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It invests predominantly in income-producing equity securities issued by infrastructure companies, including common stock, preferred stock, convertible securities, and rights or warrants to buy common stocks. The company intends to focus on three infrastructure megatrends: decarbonization, digital transformation, and asset modernization while making its investments.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.